Clinical Trial Update: Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Pfizer reports long-term safety data from a Phase 3 trial of DVS-233 SR in adults with Major Depressive Disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• DVS-233 SR

Snippet

Sponsor: Pfizer | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED